When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Guillain-Barre syndrome

Last reviewed: 21 Oct 2024
Last updated: 10 Nov 2022

Summary

Definition

History and exam

Key diagnostic factors

  • muscle weakness
  • paresthesia
  • back/leg pain
  • respiratory distress
  • speech problems
  • areflexia/hyporeflexia
  • facial weakness
  • bulbar dysfunction causing oropharyngeal weakness
  • extraocular muscle weakness
  • facial droop
  • diplopia
  • dysarthria
  • dysphagia
  • dysautonomia
  • pupillary dysfunction
  • ophthalmoplegia
Full details

Other diagnostic factors

  • ptosis
  • altered level of consciousness
  • ataxia
Full details

Risk factors

  • preceding viral illness
  • preceding bacterial infection
  • preceding mosquito-borne viral infections
  • hepatitis E infection
  • immunization
  • cancer and lymphoma
  • older age
  • HIV infection
  • COVID-19 infection
  • male
Full details

Diagnostic tests

1st tests to order

  • nerve conduction studies
  • lumbar puncture
  • LFTs
  • spirometry
Full details

Tests to consider

  • antiganglioside antibody
  • serology
  • stool culture
  • HIV antibodies
  • spinal MRI
  • Borrelia burgdorferi serology
  • cerebrospinal fluid (CSF) meningococcal polymerase chain reaction
  • CSF cytology
  • CSF angiotensin-converting enzyme
  • chest x-ray
  • CSF VDRL
  • CSF West Nile polymerase chain reaction
Full details

Emerging tests

  • ultrasound imaging of peripheral nerves

Treatment algorithm

ACUTE

ambulatory within 2 weeks of onset or nonambulatory within 4 weeks of onset

Contributors

Authors

Saiju Jacob, MD, DPhil, MRCP (UK), FRCP (Lon)

Consultant Neurologist

Queen Elizabeth Neurosciences Centre

University Hospital Birmingham

Birmingham

UK

Disclosures

SJ has served as an international advisory board member for Alexion, Alnylam, ArgenX, Regeneron, Immunovant, and UCB pharmaceuticals. He is currently an expert panel member of the Myasthenia Gravis consortium for ArgenX, and has received speaker fees from Terumo BCT and Eisai.

Acknowledgements

Dr Saiju Jacob would like to gratefully acknowledge Dr John B. Winer, Dr Michael T. Torbey, Dr Dhruvil J. Pandya, and Dr Prem A. Kandiah, previous contributors to this topic.

Disclosures

JBW, MTT, DJP, and PAK declare that they have no competing interests.

Peer reviewers

Cigdem Akman, MD

Division of Pediatric Neurology

Columbia University College of Physicians and Surgeons

New York

NY

Disclosures

CA declares that he has no competing interests.

Robert Hadden, FRCP, PhD

Consultant Neurologist

King's College Hospital

London

UK

Disclosures

RH has been paid by Baxter Healthcare Ltd for membership of its neurology advisory board, and is a co-author of several studies referenced in this topic.

  • Differentials

    • Transverse myelitis
    • Myasthenia gravis
    • Lambert-Eaton myasthenic syndrome (LEMS)
    More Differentials
  • Guidelines

    • Diagnosis and treatment of Guillain-Barre syndrome in childhood and adolescence: an evidence- and consensus-based guideline
    • Diagnosis and management of Guillain-Barré syndrome in ten steps
    More Guidelines
  • Patient information

    Lumbar puncture

    Guillain-Barre syndrome

    More Patient information
  • Videos

    Diagnostic lumbar puncture in adults: animated demonstration

    Tracheal intubation: animated demonstration

    More videos
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer